Skip to main content

Day: April 4, 2025

Atlantic Petroleum – Update on Debt

Tórshavn, Faroe Islands, 2025-04-04 (GLOBE NEWSWIRE) — P/F Atlantic Petroleum (NASDAQ OMX: ATLA DKK) provides update on debt situation. Referring to the press release issued 31st March 2025 concerning debt negotiations, Atlantic Petroleum has come to a framework agreement with its main creditors whereby the total debt will be reduced by more than DKK 90 million. The debt reduction is subject to final agreements to be finalized. Part of the debt settlement includes London Oil and Gas (in administration) converting part of its debt to shares in Atlantic Petroleum as per Clause 3E subclause 5 in Atlantic Petroleum’s Articles of Association. London Oil and Gas (in administration) will be issued 795,712 shares in P/F Atlantic Petroleum. The total number of shares would after conversion be 4,493,572, giving LOG 17.7% of the total shares...

Continue reading

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the “NYSE American” or the “Exchange”) that it had suspended trading of the Company’s common stock and of its determination to commence delisting proceedings of the Company’s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company’s common stock. The Company plans to appeal the determination to the Exchange’s Listing Qualifications Panel, although there can be...

Continue reading

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, have jointly filed a definitive proxy statement/prospectus with the U.S. Securities and Exchange Commission in connection with the...

Continue reading

ThinkCareBelieve: Week 11 America Under President Trump’s Leadership

The Celebration of America’s Liberation Washington DC, April 04, 2025 (GLOBE NEWSWIRE) — Link to ThinkCareBelieve’s Article:  https://thinkcarebelieve.blog/2025/03/31/week-11-under-president-trumps-leadership/What an amazing week this has been. So many huge strides made. ThinkCareBelieve has published an article about America’s Giant Leap into a beautiful new realm of a level playing field with trading partners in global markets with America’s rebirth of American Industry. The article covers new huge issues found in Social Security, with Social Security Numbers being used by illegals with trillions of dollars being paid out fraudulently and illegally. But that’s not the only thing DOGE has found this week- The U.S. Institute for Peace has been funding the Taliban and other terrorist groups. The...

Continue reading

Edesa Biotech Announces Chief Financial Officer Transition

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage pharmaceutical company. From August 2017 to August 2018, Mr. Weiler served as Vice President of Business Development at Biosyent Inc. Prior to that,...

Continue reading

Grayscale Investments® Announces Rebalancing of Multi-Asset Funds for First Quarter 2025

STAMFORD, Conn., April 04, 2025 (GLOBE NEWSWIRE) — Grayscale Investments®, a leading crypto asset management firm, offering more than 30 crypto investment products, and manager of Grayscale® Digital Large Cap Fund (OTCQX: GDLC) (Digital Large Cap Fund), Grayscale® Decentralized Finance (DeFi) Fund (OTCQB: DEFG) (DeFi Fund), Grayscale® Smart Contract Fund (GSC Fund), and Grayscale® Decentralized AI Fund (AI Fund), today announced the updated Fund Component weightings for each product in connection with their respective first quarter 2025 reviews. In accordance with the CoinDesk Large Cap Select Index methodology, Grayscale has adjusted GDLC’s portfolio by purchasing and selling the existing Fund Components in proportion to their respective weightings. At the end of the day on April 3, 2025, GDLC’s Fund Components were a basket of...

Continue reading

CubeSmart Announces the Date of Its First Quarter 2025 Earnings Release and Conference Call

MALVERN, Pa., April 04, 2025 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) today announced that the Company will release financial results for the three-month period ended March 31, 2025 after the market close on Thursday, May 1, 2025. An accompanying conference call will be held at 11:00 a.m. ET on Friday, May 2, 2025. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at investors.cubesmart.com. Telephone participants may join on the day of the call by dialing 1 (800) 715-9871 using conference ID number 4783436. After the live webcast, the webcast will be available on CubeSmart’s website. In addition, a telephonic replay of the call will be available through May 16, 2025 by dialing 1 (800) 770-2030 using conference ID number 4783436#. About the Company...

Continue reading

CV Holdings, Inc. Update and Financial Statements for Year Ended December 31, 2024

NEWPORT BEACH, Calif., April 04, 2025 (GLOBE NEWSWIRE) — CV Holdings, Inc. (OTC Pink Limited: CVHL) (the “Company”) today reported a net loss for the year ended December 31, 2024 of $(18,153,285) or $(0.28) per common share with weighted average common shares of 64,413,784 issued and outstanding during 2024. All outstanding warrants expired during 2024, and accordingly the net loss was also $(0.28) per diluted common share based on 64,413,784 common shares outstanding on a fully-diluted basis. The net loss for the year ended December 31, 2024 was primarily due to interest expense on preferred equity of $14,457,898 as well as the Company’s credit loss expense of $8,952,270 and interest on lines of credit and securitized debt of $8,717,228. Salaries and related payroll expenses were $7,597,857 and general and administrative expenses...

Continue reading

Giga Metals Completes Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 04, 2025 (GLOBE NEWSWIRE) — Mark Jarvis, CEO of Giga Metals Corp. (TSX.V – GIGA) (“Giga” or the “Company”) announced today that Giga has completed the non-brokered private placement (the “Private Placement”) previously announced on March 25, 2025. The Company closed 4,320,000 Units at $0.10 per Unit for gross proceeds of $432,000. Each Unit consists of one share and one share purchase warrant. Each full warrant is exercisable at Cdn. $0.15 for three years, expiring April 4, 2028. The securities issued have a hold period expiring 4 months plus one day after issuance, being August 5, 2025. Insiders participated as to 250,000 Units. No control blocks were created as a result of the private placement. Proceeds of the private...

Continue reading

AC Reports Preliminary March 31 Book Value of $42.42 to $42.62 Per Share

GREENWICH, Conn., April 04, 2025 (GLOBE NEWSWIRE) — Associated Capital Group, Inc. (“AC” or the “Company”) (NYSE:AC), announced today a preliminary range for its first quarter book value of $42.42 to $42.62 per share. This compares to $42.14 per share at December 31, 2024. AC will be issuing further details on its financial results in May. About Associated Capital Group, Inc.Associated Capital Group, Inc. (NYSE: AC), based in Greenwich, Connecticut, is a diversified global financial services company that provides alternative investment management through Gabelli & Company Investment Advisers, Inc. (“GCIA”). We have also earmarked proprietary capital for our direct investment business that invests in new and existing businesses. The direct investment business is developing along several core pillars including Gabelli Private...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.